Recent developments in computational prediction of HERG blockage.

The blockage of the voltage dependent ion channel encoded by human ether-a-go-go related gene (hERG) may lead to drug-induced QT interval prolongation, which is a critical side-effect of non-cardiovasular therapeutic agents. Therefore, identification of potential hERG channel blockers at the early stage of drug discovery process will decrease the risk of cardiotoxicity-related attritions in the later and more expensive development stage. Computational approaches provide economic and efficient ways to evaluate the hERG liability for large-scale compound libraries. In this review, the structure of the hERG channel is briefly outlined first. Then, the latest developments in the computational predictions of hERG channel blockers and the theoretical studies on modeling hERG-blocker interactions are summarized. Finally, the challenges of developing reliable prediction models of hERG blockers, as well as the strategies for surmounting these challenges, are discussed.

[1]  Michael C Sanguinetti,et al.  Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. , 2003, Molecular pharmacology.

[2]  Michael C Sanguinetti,et al.  Structural Determinants of HERG Channel Block by Clofilium and Ibutilide , 2004, Molecular Pharmacology.

[3]  Tingjun Hou,et al.  Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.

[4]  Ying Xue,et al.  Identifying hERG Potassium Channel Inhibitors by Machine Learning Methods , 2008 .

[5]  Hongmao Sun,et al.  An Accurate and Interpretable Bayesian Classification Model for Prediction of hERG Liability , 2006, ChemMedChem.

[6]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[7]  Lupei Du,et al.  The interactions between hERG potassium channel and blockers. , 2009, Current topics in medicinal chemistry.

[8]  Daniel Scherer,et al.  Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X). , 2004, Cardiovascular research.

[9]  A. Aronov.  Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. , 2006, Journal of medicinal chemistry.

[10]  Michael J Sutcliffe,et al.  Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs , 2006, Molecular Pharmacology.

[11]  Sebastian Mika,et al.  Bias-Correction of Regression Models: A Case Study on hERG Inhibition , 2009, J. Chem. Inf. Model..

[12]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[13]  Britta Nisius,et al.  Similarity-Based Classifier Using Topomers to Provide a Knowledge Base for hERG Channel Inhibition , 2009, J. Chem. Inf. Model..

[14]  Jamie I Vandenberg,et al.  Tryptophan scanning mutagenesis of the HERG K+ channel: the S4 domain is loosely packed and likely to be lipid exposed , 2005, The Journal of physiology.

[15]  Sonja Visentin,et al.  GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers. , 2009, European journal of medicinal chemistry.

[16]  S. Polak,et al.  Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties , 2009, Journal of applied toxicology : JAT.

[17]  Matthew Clark,et al.  Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..

[18]  J. Hancox,et al.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.

[19]  Michael C Sanguinetti,et al.  Regional Specificity of Human ether-a'-go-go-related Gene Channel Activation and Inactivation Gating* , 2005, Journal of Biological Chemistry.

[20]  Gisbert Schneider,et al.  A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.

[21]  Karl-Heinz Boven,et al.  Micro-Electrode Arrays in Cardiac Safety Pharmacology , 2004, Drug safety.

[22]  Serdar Kuyucak,et al.  Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel. , 2007, The journal of physical chemistry. B.

[23]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[24]  G. Keserü.  Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.

[25]  Heinz-Werner Kleemann,et al.  Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. , 2004, Bioorganic & medicinal chemistry letters.

[26]  A. Brown,et al.  Drugs, hERG and sudden death. , 2004, Cell calcium.

[27]  U. Zachariae,et al.  Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. , 2009, Journal of medicinal chemistry.

[28]  Alex M Aronov,et al.  Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.

[29]  Michael C Sanguinetti,et al.  Gating currents associated with intramembrane charge displacement in HERG potassium channels , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Dimitris K Agrafiotis,et al.  A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set , 2006, Chemical biology & drug design.

[31]  David J. Diller,et al.  In Silico hERG Modeling: Challenges and Progress , 2009 .

[32]  B. Fermini,et al.  Mechanism of action potential prolongation by RP 58866 and its active enantiomer, terikalant. Block of the rapidly activating delayed rectifier K+ current, IKr. , 1996, Circulation.

[33]  Andrea Cavalli,et al.  Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies , 2008, J. Comput. Chem..

[34]  Daniela Barlocco,et al.  Development of pharmacophores for inhibitors of the rapid component of the cardiac delayed rectifier potassium current , 1998 .

[35]  Serdar Kuyucak,et al.  The Pore Domain Outer Helix Contributes to Both Activation and Inactivation of the hERG K+ Channel* , 2009, Journal of Biological Chemistry.

[36]  Lawrence M. Seiford,et al.  Recent developments in dea : the mathematical programming approach to frontier analysis , 1990 .

[37]  Steffen Hering,et al.  The hERG Potassium Channel and Drug Trapping: Insight from Docking Studies with Propafenone Derivatives , 2010, ChemMedChem.

[38]  M. Sutcliffe,et al.  Drug block of the hERG potassium channel: Insight from modeling , 2007, Proteins.

[39]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[40]  Ronald Wilders,et al.  A Common Antitussive Drug, Clobutinol, Precipitates the Long QT Syndrome 2 , 2004, Molecular Pharmacology.

[41]  Katsumi Yoshida,et al.  Quantitative Structure-Activity Relationship Studies on Inhibition of HERG Potassium Channels , 2006, J. Chem. Inf. Model..

[42]  Michael J A Walker,et al.  Physicochemical determinants for drug induced blockade of HERG potassium channels: effect of charge and charge shielding. , 2003, Current medicinal chemistry. Cardiovascular and hematological agents.

[43]  Yadong Chen,et al.  Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models , 2012, Journal of Molecular Modeling.

[44]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[45]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[46]  Jules C Hancox,et al.  High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. , 2004, Biochemical and biophysical research communications.

[47]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[48]  Andreas Bender,et al.  Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases , 2010, ChemMedChem.

[49]  Gea-Ny Tseng,et al.  Gating Charges in the Activation and Inactivation Processes of the hERG Channel , 2004, The Journal of general physiology.

[50]  Tingjun Hou,et al.  Recent developments of in silico predictions of intestinal absorption and oral bioavailability. , 2009, Combinatorial chemistry & high throughput screening.

[51]  Jules C Hancox,et al.  The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping , 2004, Molecular Pharmacology.

[52]  Raimund Mannhold,et al.  QSAR modeling and data mining link Torsades de Pointes risk to the interplay of extent of metabolism, active transport, and HERG liability. , 2012, Molecular pharmaceutics.

[53]  G. Robertson,et al.  Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E‐4031 from HERG to M‐eag channels , 1998, The Journal of physiology.

[54]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[55]  Sean Ekins,et al.  Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. , 2006, Journal of medicinal chemistry.

[56]  T. Nishikawa,et al.  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[57]  Hongmao Sun,et al.  Support vector machines classification of hERG liabilities based on atom types. , 2008, Bioorganic & medicinal chemistry.

[58]  Kaichiro Kamiya,et al.  Molecular Determinants of hERG Channel Block , 2006, Molecular Pharmacology.

[59]  Gea-Ny Tseng,et al.  Structural and Functional Role of the Extracellular S5-P Linker in the HERG Potassium Channel , 2002, The Journal of general physiology.

[60]  Junmei Wang,et al.  Structure – ADME relationship: still a long way to go? , 2008, Expert opinion on drug metabolism & toxicology.

[61]  Tudor I. Oprea,et al.  hERG classification model based on a combination of support vector machine method and GRIND descriptors. , 2008, Molecular pharmaceutics.

[62]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[63]  Youyong Li,et al.  ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage. , 2012, Molecular pharmaceutics.

[64]  Tamanna Gandhi,et al.  Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques. , 2008, Journal of molecular graphics & modelling.

[65]  Gert Vriend,et al.  Toward a Consensus Model of the hERG Potassium Channel , 2010, ChemMedChem.

[66]  Gary Yellen,et al.  Fast and Slow Voltage Sensor Movements in HERG Potassium Channels , 2002, The Journal of general physiology.

[67]  Bernd Beck,et al.  A Composite Model for hERG Blockade , 2008, ChemMedChem.

[68]  Tatsuya Takagi,et al.  Nonlinear classification of hERG channel inhibitory activity by unsupervised classification method. , 2010, The Journal of toxicological sciences.

[69]  Tim S. Munsey,et al.  Movement of the S4 segment in the hERG potassium channel during membrane depolarization , 2009, Molecular membrane biology.

[70]  Flemming Steen Jørgensen,et al.  In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. , 2011, Combinatorial chemistry & high throughput screening.

[71]  Maurizio Recanatini,et al.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.

[72]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[73]  G. Ecker,et al.  A binary QSAR model for classification of hERG potassium channel blockers. , 2008, Bioorganic & medicinal chemistry.

[74]  A. Bianucci,et al.  Prediction of hERG potassium channel affinity by the CODESSA approach. , 2006, Bioorganic & medicinal chemistry.

[75]  J. Mitcheson.  hERG potassium channels and the structural basis of drug-induced arrhythmias. , 2008, Chemical research in toxicology.

[76]  Antranig Basman,et al.  HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. , 2004, Progress in biophysics and molecular biology.

[77]  Gerhard F. Ecker,et al.  Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers , 2009, Molecular Diversity.

[78]  Wei Zhang,et al.  Recent advances in computational prediction of drug absorption and permeability in drug discovery. , 2006, Current medicinal chemistry.

[79]  Haruhiko Abe,et al.  Blockade of HERG cardiac K+ current by antifungal drug miconazole , 2005, British journal of pharmacology.

[80]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[81]  Lin Xia,et al.  The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. , 2004, Bioorganic & medicinal chemistry letters.

[82]  V. Poroikov,et al.  Computer-aided prediction of QT-prolongation , 2008, SAR and QSAR in environmental research.

[83]  François Petitet,et al.  In Silico Classification of hERG Channel Blockers: a Knowledge‐Based Strategy , 2006, ChemMedChem.

[84]  C. Leem,et al.  A novel hypothesis for the binding mode of HERG channel blockers. , 2006, Biochemical and biophysical research communications.

[85]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[86]  Srikanta Sen,et al.  Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. , 2011, European journal of medicinal chemistry.

[87]  Bo-Han Su,et al.  Predictive Toxicology Modeling: Protocols for Exploring hERG Classification and Tetrahymena pyriformis End Point Predictions , 2012, J. Chem. Inf. Model..

[88]  Lu Chen,et al.  A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling , 2011, J. Chem. Inf. Model..

[89]  Sean Ekins,et al.  Shape signatures: new descriptors for predicting cardiotoxicity in silico. , 2008, Chemical research in toxicology.

[90]  Jamie I Vandenberg,et al.  Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. , 2008, Progress in biophysics and molecular biology.

[91]  M. Sutcliffe,et al.  Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations. , 2008, Biochemistry.

[92]  Jamie I Vandenberg,et al.  Molecular basis of slow activation of the human ether‐á‐go‐go related gene potassium channel , 2004, The Journal of physiology.

[93]  H. Guy,et al.  Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling. , 2007, Biophysical journal.

[94]  Bo-Han Su,et al.  In Silico Binary Classification QSAR Models Based on 4D-Fingerprints and MOE Descriptors for Prediction of hERG Blockage , 2010, J. Chem. Inf. Model..

[95]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[96]  B. L. de Groot,et al.  Computer simulations of structure-activity relationships for HERG channel blockers. , 2011, Biochemistry.